Pulmatrix, Inc. filings document material events for a biopharmaceutical issuer developing inhaled therapeutic candidates through its iSPERSE platform. The record includes Form 8-K disclosures on operating and financial results, corporate updates, clinical or regulatory matters, material agreements, shareholder voting matters, governance actions and capital-structure information.
These filings also capture Regulation FD communications and other event reports tied to Pulmatrix's public-company reporting obligations, including disclosures related to strategic transaction agreements and related governance matters.
Pulmatrix, Inc. presented preclinical findings from Eos SENOLYTIX, Inc. on PTC-2105 and late-life lean-mass change in aged mice. In one high-fat-diet cohort, the study reported a terminal lean-mass rate of +0.005 g/wk with PTC-2105 alone versus -0.002 g/wk with saline. In a second cohort, rates were -0.055 g/wk with semaglutide alone and +0.009 g/wk with PTC-2105 alone; the two PTC-2105-plus-semaglutide arms reported +0.126 and -0.011 g/wk. These are findings from aged-mouse studies.
Pulmatrix and Eos have a proposed merger under which Eos would become Pulmatrix’s wholly owned subsidiary. Pulmatrix’s special meeting is scheduled for October 26, 2026, unless postponed or adjourned; the merger is anticipated to close shortly afterward, subject to satisfaction or waiver of customary closing conditions. If completed, the combined company’s common stock is expected to trade on Nasdaq under the ticker MTXL.
Pulmatrix, Inc. (PULM) postponed its special meeting from October 16, 2026, to October 26, 2026, at 8:30 a.m. Eastern Time; the meeting will be held exclusively online. Pulmatrix said the postponement gives stockholders additional time to receive and review the supplement and annual report and submit their votes. The record date remains August 28, 2026, and Proposals 1 through 9 are unchanged. Proxies must be received by 11:59 p.m. Eastern Time on October 25, 2026. Previously submitted proxies remain valid unless properly revoked, and a later-dated proxy replaces an earlier one. Stockholders seeking additional documents should request them by October 19, 2026, to receive them before the meeting.
For the 2027 annual meeting, proposals for inclusion in the proxy materials must be submitted by May 28, 2027. Director nominations and proposals to be presented outside the proxy materials must be received between June 28 and July 28, 2027, subject to the stated exception if the meeting is held more than 30 days before or after the anniversary of the special meeting.
Pulmatrix, Inc. registers for resale by RCM Eos PIPE HOLDINGS, LLC up to an aggregate of 491,607 shares of Common Stock, issuable upon conversion of Series B preferred stock and as dividends. The selling stockholder may not sell the shares until the registration statement is effective. Pulmatrix will receive no proceeds from resales; it will pay registration expenses, while the selling stockholder bears any commissions and discounts.
The registered shares include 454,546 conversion shares and up to 37,061 dividend shares. The preferred shares carry a $2.20 per-share conversion price and cumulative dividends at 8% per annum, payable in common stock. Pulmatrix states that the maximum registered issuance represents approximately 13% of common shares outstanding and could substantially dilute existing stockholders; 3,652,285 common shares were issued and outstanding as of September 29, 2026. A 9.99% beneficial ownership limit restricts conversion by the holder and its affiliates.
Pulmatrix, Inc. registered 75,245,366 shares of common stock for issuance in its proposed merger with Eos SENOLYTIX Inc. The total comprises 54,359,630 shares for Eos stockholders and investors in concurrent financings, plus 20,885,736 additional securities for new warrants, options and restricted stock units. At closing, Eos would survive as a wholly owned Pulmatrix subsidiary. The estimated exchange ratio is approximately 8.55 Pulmatrix shares per Eos capital-stock share, based on capitalization and share-purchase commitments as of August 28, 2026, and does not reflect the proposed reverse split.
Pulmatrix stockholders are scheduled to vote October 16, 2026; merger completion requires approval of the stock-issuance, reverse-split and authorized-share proposals, as well as other closing conditions. The proposed reverse split is one new share for every 2 to 10 outstanding shares, with the ratio determined by Pulmatrix’s board and agreed to by Eos; authorized common shares would increase from 200,000,000 to 250,000,000. Eos must receive at least $13,000,000 in aggregate gross cash proceeds from financing transactions at closing or substantially simultaneously with it; bridge financing of $5,000,000 or less is excluded from that calculation. Existing Pulmatrix holders are estimated to own approximately 6% of the combined company, excluding CEO RSUs; SENOTHERAPEUTIX is expected to hold more than 50% of its voting power.
Pulmatrix, Inc. (PULM) seeks approval for its proposed merger with Eos SENOLYTIX Inc.; 75,245,366 common shares are registered for issuance in the transaction. Eos would survive as Pulmatrix’s wholly owned subsidiary. The estimated exchange ratio is approximately 8.55 Pulmatrix shares per Eos capital-stock share, based on capitalization and purchase commitments as of August 28, 2026; it is subject to adjustment and excludes the proposed reverse stock split. Pulmatrix securityholders are expected to own approximately 6%, and Eos securityholders 94%, on a fully diluted basis excluding CEO RSUs. SENOTHERAPEUTIX, Inc. is expected to hold more than 50% of voting power; the combined company will be a controlled company.
Completion requires approval of Pulmatrix’s stock issuance, reverse stock split and authorized-share increase proposals. At closing, Eos must receive, or receive substantially simultaneously, at least $13,000,000 in aggregate gross cash proceeds from financing transactions; bridge financing totaling $5,000,000 or less is excluded. The split proposal seeks one new share for every 2 to 10 existing shares; the authorized-share proposal would raise common shares from 200,000,000 to 250,000,000. Closing is anticipated in the fourth quarter of 2026. If the merger does not close, Pulmatrix says it will have limited ability to continue its current operations indefinitely.
Pulmatrix, Inc. amended its Form S-4 solely to remove Exhibit 99.9 from Part II. The amendment consists of the cover page, explanatory note, Item 21 exhibit list, and signature pages.
Pulmatrix, Inc. (PULM) reports that merger partner Eos SENOLYTIX plans to highlight its mitochondria-targeted MitoXcel™ geropeptide platform and lead candidate PTC-2105 at the 17th World Congress on Targeting Mitochondria 2026 in Berlin, where Eos’s CEO will deliver the industry keynote and co-host a scientific panel.
Eos is advancing PTC-2105, a preclinical MitoXcel™ geropeptide aimed at treating sarcopenia and sarcopenic obesity, supported by IND-enabling studies led by academic experts. Pulmatrix and Eos expect their previously announced merger to close in the fourth quarter of 2026, subject to stockholder approval at an October 16, 2026 special meeting and other customary closing conditions, after which the combined company is expected to trade under the ticker MTXL with merger-associated financings anticipated to support pipeline progress.
Pulmatrix, Inc. (PULM) filed Amendment No. 3 to its Form S-4 to register 75,245,366 shares of common stock to be issued in connection with its proposed all‑stock merger with Eos SENOLYTIX Inc. At the merger’s effective time, Pulmatrix expects to issue 54,359,630 shares to Eos stockholders and investors in concurrent financings, plus 20,885,736 additional securities for new warrants, options and RSUs. Existing Pulmatrix securities (about 4.0 million at signing, including 3.7 million common shares and 0.3 million underlying options and warrants) will remain outstanding, subject to a proposed 1‑for‑2 to 1‑for‑10 reverse stock split and an increase in authorized common shares from 200 million to 250 million. Based on an estimated exchange ratio of 8.55 Pulmatrix shares per Eos share and current capitalizations, Pulmatrix holders are expected to own about 6% of the combined company on a fully diluted basis (excluding CEO RSUs), with 94% held by Eos stakeholders and Palladium. Eos is valued at $100.0 million pre‑money plus $19.0 million of additional investments, implying approximately $7.85 million of value for Pulmatrix’s 6% stake. SENOTHERAPEUTIX, Inc. is expected to beneficially own more than 50% of the combined company’s voting power, making it a Nasdaq “controlled company.” Closing is conditioned on Pulmatrix stockholder approval of the Nasdaq stock issuance, reverse split and authorized share increase, Nasdaq listing of the combined company (to be renamed “Eos SENOLYTIX Inc.” and trade under “MTXL”), and Eos receiving at least $13,000,000 of qualifying financing proceeds.